16 March 2016 - The drug maker is having a problem in getting physicians to prescribe Entresto.

In July, Novartis AG won regulatory approval for a new heart-failure pill that it called “one of the most remarkable drugs in cardiovascular medicine in the last several decades.” Since then, it has faced a problem: getting doctors to prescribe it.

For more details, go to: http://www.wsj.com/articles/novartis-heart-failure-pill-falls-short-of-sales-expectations-1458155650?mod=europe&mod=djemITPE_h